US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

272.07

-0.3100-0.11%

Post-market: 272.070.00000.00%19:30 EDT

Volume:61.75K

Turnover:16.80M

Market Cap:2.95B

PE:31.84

High:273.14

Open:271.38

Low:270.78

Close:272.38

52wk High:273.14

52wk Low:171.06

Shares:10.85M

Float Shares:10.85M

Volume Ratio:0.74

T/O Rate:0.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:2.22

PE(LYR):7.21

Loading ...

Overview Company News Filings

Brookfield in Exclusive Talks to Acquire Stake in Hudson Square Portfolio, Betting on Manhattan's Tech Hub

Alkermes Plc : JP Morgan Resumes Coverage with Neutral Rating; Target Price $60

THOMSON REUTERS

Bruker Files Form 3 for BMID Group President Wolfgang Pusch Stake

Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Veracyte to Report Q2 Results, Host Conference Call

Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)

NeoGenomics Launches First FDA-Approved Prostate Cancer Companion Diagnostic

Veracyte Inc : Morgan Stanley Raises Target Price to $47.00 from $37.00

THOMSON REUTERS

NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic

Neogenomics Launches Fda-approved Pten Ihc Companion Diagnostic for Prostate Cancer

THOMSON REUTERS

Corcept Chief Development Officer William Guyer Disposes of USD 1.87 Million in Common Shares

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)

Alkermes - no Penalties or Further Obligations Owed by Alkermes or Amneal After Agreement Termination - SEC Filing

THOMSON REUTERS

Alkermes - Co and Amneal Terminate Authorized Generic Product Supply Agreement on July 6, 2026 - SEC Filing

THOMSON REUTERS

StemRIM Wins South Korean Patent for Gene Therapy Targeting Rare Skin Disorder

Press Release: Neogenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

Bruker Corp : Leerink Partners Raises Target Price to $70 from $60

THOMSON REUTERS

Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $109,882.02

Corcept Endocrinology President Sean Maduck Sells USD 2.19 Million of Corcept Therapeutics Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/FBT/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":272.07,"timestamp":1787774400000,"preClose":272.38,"halted":0,"volume":61745,"hourTrading":{"tag":"盘后","latestPrice":272.07,"preClose":272.07,"latestTime":"19:30 EDT","volume":33,"amount":8982.01,"timestamp":1787787003504,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0011381158675380068,"floatShares":10850002,"shares":10850002,"eps":8.545272,"marketStatus":"Closed","change":-0.31,"latestTime":"08-26 16:00:00 EDT","open":271.38,"high":273.14,"low":270.7821,"amount":16796614.6051,"amplitude":0.008657,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787817600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":272.38,"sharesOutstanding":11450002,"nav":272.51,"aum":2970359545.02,"bidAskSpread":0.000914,"preHourTrading":{"tag":"盘前","latestPrice":272.38,"preClose":272.38,"latestTime":"08:15 EDT","volume":2,"amount":544.76,"timestamp":1787746518358,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":272.07,"preClose":272.07,"latestTime":"19:30 EDT","volume":33,"amount":8982.01,"timestamp":1787787003504,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.740746,"impliedVol":0.2406,"impliedVolPercentile":0.8924},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10850002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":0.740746,"shares":10850002,"dividePrice":0,"high":273.14,"amplitude":0.008657,"preClose":272.38,"low":270.7821,"week52Low":171.0601,"pbRate":"2.22","psRate":"1086.92","week52High":273.14,"institutionHeld":0,"latestPrice":272.07,"eps":8.545272,"divideRate":0,"volume":61745,"delay":0,"ttmEps":8.545272,"open":271.38,"prevYearClose":206.52,"prevWeekClose":270.9465,"prevMonthClose":245.06,"prevQuarterClose":247.89,"fiveDayClose":271.87,"twentyDayClose":250.47,"sixtyDayClose":220.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1113947751","title":"Brookfield in Exclusive Talks to Acquire Stake in Hudson Square Portfolio, Betting on Manhattan's Tech Hub","url":"https://stock-news.laohu8.com/highlight/detail?id=1113947751","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113947751?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:21","pubTimestamp":1783930870,"startTime":"0","endTime":"0","summary":"Real estate giant Brookfield is in exclusive negotiations to acquire a stake in Hudson Square Properties, a deal valuing the portfolio at $3.5 billion and further cementing the status of Manhattan's...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TINY","LU1815336091.USD","BK4121","FBT","BRKR","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651193713","title":"Alkermes Plc : JP Morgan Resumes Coverage with Neutral Rating; Target Price $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2651193713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651193713?lang=en_us&edition=fundamental","pubTime":"2026-07-13 13:58","pubTimestamp":1783922324,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F04A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","MEDX","ALKS","BK4139","FBT","PSIL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650813759","title":"Bruker Files Form 3 for BMID Group President Wolfgang Pusch Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2650813759","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650813759?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:28","pubTimestamp":1783715316,"startTime":"0","endTime":"0","summary":"Bruker files Form 3 for BMID Group President Wolfgang Pusch stakeBruker Form 3 showed Wolfgang Pusch, president of the BMID Group, held 10,154 shares of common stock as of July 1, 2026.Disclaimer:This","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL1vLFQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRKR","TINY","LU1815336091.USD","BK4121","LU0757428866.USD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650972435","title":"Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650972435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650972435?lang=en_us&edition=fundamental","pubTime":"2026-07-10 05:10","pubTimestamp":1783631400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--July 09, 2026--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4099","FBT","TM","03160","BK4022","BK4139","VCYT","BK4555","BK4585","R","BK4604","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650974538","title":"Veracyte to Report Q2 Results, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2650974538","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650974538?lang=en_us&edition=fundamental","pubTime":"2026-07-10 04:05","pubTimestamp":1783627519,"startTime":"0","endTime":"0","summary":"Veracyte to report Q2 results, host conference callVeracyte schedules release of second-quarter 2026 financial results for July 30, 2026.Management to host a conference call, webcast on July 30, 2026 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL9vhjk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650976961","title":"Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650976961","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650976961?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:32","pubTimestamp":1783614761,"startTime":"0","endTime":"0","summary":"What Corcept’s Index Removal Could Mean for Investors\nCorcept Therapeutics (CORT) was recently removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, a shift that can influence trading activity as index funds rebalance positions.\nFor you as an investor, these index changes are less about Corcept Therapeutics business operations and more about how institutional owners that track these benchmarks may adjust their holdings. Such rebalancing can affect short...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CORT","LU1559883803.SGD","PSCH","LU0566484027.USD","BK4532","BK4007","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650292217","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650292217","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650292217?lang=en_us&edition=fundamental","pubTime":"2026-07-09 21:10","pubTimestamp":1783602606,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Immunome (IMNM) with bullish sen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM","BK4137","LABU","XBI","PSCH","XLV","BK4585","BK4563","HCSG","BK4139","ALKS","PSIL","LU0029874061.USD","BK4588","IBRN","MEDX","LU0128526141.USD","FBT","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112561177","title":"NeoGenomics Launches First FDA-Approved Prostate Cancer Companion Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=1112561177","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112561177?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:50","pubTimestamp":1783601450,"startTime":"0","endTime":"0","summary":"NeoGenomics (NASDAQ: NEO) has announced the launch of the PTEN IHC CDx assay, the first immunohistochemistry companion diagnostic for prostate adenocarcinoma patients to receive approval from the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEO","LABU","BK4196","BK4585","BK4121","FBT","LU0106261612.USD","LU0012050646.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650592935","title":"Veracyte Inc : Morgan Stanley Raises Target Price to $47.00 from $37.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2650592935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650592935?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:32","pubTimestamp":1783596774,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nAZN4T6V3M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VCYT","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650926253","title":"NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2650926253","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650926253?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:10","pubTimestamp":1783595410,"startTime":"0","endTime":"0","summary":"NeoGenomics (NEO) announced the launch of PTEN IHC CDx, the first immunohistochemistry companion diagnostic test approved by the FDA for patients w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neogenomics-launches-fda-approved-pten-ihc-prostate-cancer-ompanion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neogenomics-launches-fda-approved-pten-ihc-prostate-cancer-ompanion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","LU0012050646.USD","BK4092","BK4121","BK4585","LABU","FBT","LU0106261612.USD","BK4588","NEO","BK4162","PTEN","IHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650591926","title":"Neogenomics Launches Fda-approved Pten Ihc Companion Diagnostic for Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2650591926","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650591926?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:05","pubTimestamp":1783595106,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nFWN43B0XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","LU0012050646.USD","NEO","LU0106261612.USD","BK4196","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650914871","title":"Corcept Chief Development Officer William Guyer Disposes of USD 1.87 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650914871","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650914871?lang=en_us&edition=fundamental","pubTime":"2026-07-09 07:55","pubTimestamp":1783554932,"startTime":"0","endTime":"0","summary":"Corcept Chief Development Officer William Guyer disposes of USD 1.87 million in common sharesCorcept: Chief Development Officer William Guyer exercised options for 20,000 common shares at USD 21.65 on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL7XHH1p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Development Officer William Guyer Disposes of USD 1.87 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1559883803.SGD","BK4007","CORT","FBT","PSCH","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650997530","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650997530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650997530?lang=en_us&edition=fundamental","pubTime":"2026-07-08 23:50","pubTimestamp":1783525804,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-evolus-eols-alkermes-alks-and-volitionrx-vnrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-evolus-eols-alkermes-alks-and-volitionrx-vnrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","EOLS","IBRN","BK4581","BK4585","BK4139","VNRX","BK4588","BK4198","PSCH","LU0029874061.USD","XBI","HCSG","PSIL","ALKS","FBT","MEDX","LABU","BK4137","BK4007","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649993013","title":"Alkermes - no Penalties or Further Obligations Owed by Alkermes or Amneal After Agreement Termination - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2649993013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649993013?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:05","pubTimestamp":1783512335,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nFWN43A0A0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","MEDX","PSIL","PSCH","FBT","BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649017993","title":"Alkermes - Co and Amneal Terminate Authorized Generic Product Supply Agreement on July 6, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2649017993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649017993?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:05","pubTimestamp":1783512335,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nFWN43A0A0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBT","MEDX","PSIL","PSCH","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649963787","title":"StemRIM Wins South Korean Patent for Gene Therapy Targeting Rare Skin Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2649963787","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649963787?lang=en_us&edition=fundamental","pubTime":"2026-07-08 14:54","pubTimestamp":1783493684,"startTime":"0","endTime":"0","summary":"StemRIM Inc. ( ($JP:4599) ) has shared an update. StemRIM Inc. has secured patent protection in South Korea for a stem cell gene therapy technology...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stemrim-wins-south-korean-patent-for-gene-therapy-targeting-rare-skin-disorder?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stemrim-wins-south-korean-patent-for-gene-therapy-targeting-rare-skin-disorder?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","CNCR","FBT","LFSC","IBB","USRD","BK4585","IBBQ","SYNB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984850","title":"Press Release: Neogenomics to Report Second Quarter 2026 Financial Results on July 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984850","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984850?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:06","pubTimestamp":1783422360,"startTime":"0","endTime":"0","summary":"FORT MYERS, Fla.--(BUSINESS WIRE)--July 07, 2026--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will repo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","LU0012050646.USD","NEO","BK4121","FBT","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649989716","title":"Bruker Corp : Leerink Partners Raises Target Price to $70 from $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2649989716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649989716?lang=en_us&edition=fundamental","pubTime":"2026-07-07 18:15","pubTimestamp":1783419305,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BRKR","TINY","LU0757428866.USD","LU1815336091.USD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649671125","title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $109,882.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2649671125","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649671125?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:49","pubTimestamp":1783370958,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $109,882.02Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on July 6, 2026.Shares were sold at USD 54.0","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL5RNxXp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $109,882.02","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","IBRN","FBT","PSCH","MEDX","ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649711546","title":"Corcept Endocrinology President Sean Maduck Sells USD 2.19 Million of Corcept Therapeutics Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2649711546","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649711546?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:45","pubTimestamp":1783370708,"startTime":"0","endTime":"0","summary":"Corcept Endocrinology President Sean Maduck sells USD 2.19 million of Corcept Therapeutics sharesSean Maduck, President, Corcept Endocrinology at Corcept Therapeutics, reported option exercise and share sales dated July 1, 2026.Exercised stock options for 25,000 shares at USD 8.27.Sold 24,?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDLZG90m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Endocrinology President Sean Maduck Sells USD 2.19 Million of Corcept Therapeutics Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","LU1559883803.SGD","BK4532","BK4007","CORT","PSCH","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}